SPX3,963.94-62.18 -1.54%
DIA338.49-5.03 -1.46%
IXIC11,049.50-176.86 -1.58%

Citigroup Maintains Buy on Fate Therapeutics, Lowers Price Target to $80

Benzinga · 11/16/2022 07:59
Citigroup analyst Yigal Nochomovitz maintains Fate Therapeutics (NASDAQ:FATE) with a Buy and lowers the price target from $87 to $80.